1. Home
  2. Stocks
  3. Pplpharma Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Piramal Pharma Share Price

    Large Cap
    ₹217.34
    -8.97 (-3.96%)
    10 September, 2024 05:57 BSE: 543635 NSE: PPLPHARMA ISIN: INE0DK501011

    Start SIP in Piramal Pharma

    Start SIP

    Piramal Pharma Performance

    Day Range

    • Low 215
    • High 227
    ₹ 217

    52 Week Range

    • Low 88
    • High 228
    ₹ 217
    • Open Price225
    • Previous Close226
    • Volume13710460

    Piramal Pharma Chart

    • Over 1 Month + 17.45%
    • Over 3 Month + 44.89%
    • Over 6 Month + 71.27%
    • Over 1 Year + 105.52%

    Piramal Pharma Key Statistics

    P/E Ratio 1038
    PEG Ratio 9
    Market Cap Cr
    Price to Book Ratio 3.6
    EPS 2.9
    Dividend 0.1
    Relative Strength Index 71.72
    Money Flow Index 85.86
    MACD Signal 8.51
    Average True Range 8.46

    Piramal Pharma Investment Rating

    • Master Rating:

    • Piramal Pharma has an operating revenue of Rs. 8,373.45 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 31%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 30% and 54% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Piramal Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,0631,5251,0249948461,055
    Operating Expenses Qtr Cr 9121,136899908830965
    Operating Profit Qtr Cr 152390126861790
    Depreciation Qtr Cr 525352515053
    Interest Qtr Cr 252817283434
    Tax Qtr Cr 26901519-824
    Net Profit Qtr Cr 852737477-3342
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,5923,784
    Operating Expenses Annual Cr 3,7723,346
    Operating Profit Annual in Cr 61898
    Depreciation Cr 205192
    Interest Annual Cr 107116
    Tax Annual Cr 11654
    Net Profit Annual Cr 39170
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 35872
    Cash from Investing Activity Annual Cr -636-435
    Cash from Financing Annual Activity Cr 451290
    Net Cash Flow Annual Cr 174-73
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 6,7125,262
    Fixed Assets Annual Cr 3,1453,018
    Total Non Current Assets Annual Cr 6,2595,694
    Total Current Assets Annual Cr 3,2922,349
    Total Assets Annual Cr 9,5518,042
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 5144
    ROE Annual % 61
    ROCE Annual % 84
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1913
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,9512,5521,9591,9111,7492,164
    Operating Expenses Qtr Cr 1,7472,0221,6901,6461,6171,812
    Operating Profit Qtr Cr 204530268266132351
    Depreciation Qtr Cr 185196186185174184
    Interest Qtr Cr 107114106110119104
    Tax Qtr Cr 44126935-945
    Net Profit Qtr Cr -89101105-9950
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 8,3477,307
    Operating Expenses Annual Cr 6,9756,453
    Operating Profit Annual in Cr 1,196628
    Depreciation Cr 741677
    Interest Annual Cr 448344
    Tax Annual Cr 16166
    Net Profit Annual Cr 18-186
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,005484
    Cash from Investing Activity Annual Cr -434-1,339
    Cash from Financing Annual Activity Cr -422818
    Net Cash Flow Annual Cr 148-37
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 7,9116,774
    Fixed Assets Annual Cr 7,9837,780
    Total Non Current Assets Annual Cr 9,8479,687
    Total Current Assets Annual Cr 5,4644,835
    Total Assets Annual Cr 15,31214,523
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 6057
    ROE Annual % 0-3
    ROCE Annual % 62
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1712
    Invest in Piramal Pharma

    Piramal Pharma Technicals

    EMA & SMA

    Current Price
    ₹217.34
    -8.97 (-3.96%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹195.47
    • 50 Day
    • ₹179.79
    • 100 Day
    • ₹166.01
    • 200 Day
    • ₹150.10
    • 20 Day
    • ₹193.02
    • 50 Day
    • ₹174.71
    • 100 Day
    • ₹162.07
    • 200 Day
    • ₹147.42

    Piramal Pharma Resistance and Support

    PIVOT
    ₹219.61
    Resistance
    First Resistance 224.47
    Second Resistance 231.60
    Third Resistance 236.46
    RSI 71.72
    MFI 85.86
    MACD Single Line 8.51
    MACD 11.58
    Support
    First Support 212.48
    Second Support 207.62
    Third Supoort 200.49

    Piramal Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 14,282,345 263,652,089 18.46
    Week 31,221,421 522,646,591 16.74
    1 Month 10,956,358 272,046,358 24.83
    6 Month 6,601,404 246,496,441 37.34

    Piramal Pharma Result Highlights

    Piramal Pharma Synopsis

    NSE-Medical-Diversified

    Piramal Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4390.11 Cr. and Equity Capital is Rs. 1322.95 Cr. for the Year ended 31/03/2024. Piramal Pharma Ltd. is a Public Limited Listed company incorporated on 04/03/2020 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24297MH2020PLC338592 and registration number is 338592.
    Market Cap 28,814
    Sales 4,607
    Shares in Float 86.17
    No of funds 212
    Yield 0.05
    Book Value 4.28
    U/D Vol ratio 3.5
    LTDebt / Equity 5
    Alpha 0.23
    Beta 0.8

    Piramal Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 34.95%35.02%35.02%35.02%
    Mutual Funds 10.12%9.01%6.28%3.8%
    Insurance Companies 2.43%2.64%2.88%3.8%
    Foreign Portfolio Investors 13.41%12.54%14.47%14.33%
    Financial Institutions/ Banks
    Individual Investors 13.93%15.13%15.57%16.95%
    Others 25.16%25.66%25.78%26.1%

    Piramal Pharma Management

    Name Designation
    Mrs. Nandini Piramal Chairperson
    Mr. Vivek Valsaraj Executive Director & CFO
    Mr. Peter DeYoung Executive Director
    Mr. Neeraj Bharadwaj Non Executive Director
    Ms. Vibha Paul Rishi Independent Director
    Mr. Jairaj Purandare Independent Director
    Mr. Peter Stevenson Independent Director
    Mr. S Ramadorai Independent Director
    Mr. Sridhar Gorthi Independent Director

    Piramal Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Piramal Pharma Corporate Action

    Date Purpose Remarks
    2024-07-26 Quarterly Results
    2024-05-10 Audited Results & Final Dividend
    2024-01-30 Quarterly Results
    2023-10-27 Quarterly Results
    2023-08-03 Quarterly Results
    Date Purpose Remarks
    2024-07-12 FINAL Rs.0.11 per share(1.1%)Final Dividend

    Piramal Pharma MF Shareholding

    Name Amount(cr)
    HDFC Flexi Cap Fund Growth 61,572
    ICICI Prudential Value Discovery Fund Growth 48,806
    ICICI Prudential Equity & Debt Fund Growth 39,091
    HDFC Focused 30 Fund Growth 13,795
    Canara Robeco Small Cap Fund Regular Growth 12,248

    Piramal Pharma FAQs

    What is Share Price of Piramal Pharma ?

    Piramal Pharma share price is ₹217 As on 10 September, 2024 | 05:43

    What is the Market Cap of Piramal Pharma ?

    The Market Cap of Piramal Pharma is ₹28813.8 Cr As on 10 September, 2024 | 05:43

    What is the P/E ratio of Piramal Pharma ?

    The P/E ratio of Piramal Pharma is 1038 As on 10 September, 2024 | 05:43

    What is the PB ratio of Piramal Pharma ?

    The PB ratio of Piramal Pharma is 3.6 As on 10 September, 2024 | 05:43

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.